- Home
- IONS vs VNT Comparison
IONS vs VNT Comparison
Compare IONS & VNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- VNT
- Stock Information
- Founded
- IONS 1989
- VNT 2019
- Country
- IONS United States
- VNT United States
- Employees
- IONS N/A
- VNT N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- VNT Industrial Machinery/Components
- Sector
- IONS Health Care
- VNT Industrials
- Exchange
- IONS Nasdaq
- VNT Nasdaq
- Market Cap
- IONS 4.6B
- VNT 4.4B
- IPO Year
- IONS 1991
- VNT N/A
- Fundamental
- Price
- IONS $32.26
- VNT $34.86
- Analyst Decision
- IONS Buy
- VNT Buy
- Analyst Count
- IONS 18
- VNT 7
- Target Price
- IONS $57.41
- VNT $42.80
- AVG Volume (30 Days)
- IONS 1.7M
- VNT 1.0M
- Earning Date
- IONS 04-30-2025
- VNT 05-01-2025
- Dividend Yield
- IONS N/A
- VNT 0.29%
- EPS Growth
- IONS N/A
- VNT N/A
- EPS
- IONS N/A
- VNT 2.46
- Revenue
- IONS $717,253,000.00
- VNT $2,964,300,000.00
- Revenue This Year
- IONS N/A
- VNT $2.45
- Revenue Next Year
- IONS $27.39
- VNT $4.72
- P/E Ratio
- IONS N/A
- VNT $14.21
- Revenue Growth
- IONS N/A
- VNT N/A
- 52 Week Low
- IONS $23.95
- VNT $27.22
- 52 Week High
- IONS $52.34
- VNT $41.61
- Technical
- Relative Strength Index (RSI)
- IONS 57.55
- VNT 68.82
- Support Level
- IONS $31.66
- VNT $33.06
- Resistance Level
- IONS $33.98
- VNT $33.95
- Average True Range (ATR)
- IONS 1.30
- VNT 0.89
- MACD
- IONS 0.41
- VNT 0.57
- Stochastic Oscillator
- IONS 68.84
- VNT 91.82
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About VNT Vontier Corporation
Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3 billion in sales in 2024.